Bayer Pharma AG

Essence of this Article

Several new anticoagulants that target various factors of the coagulation cascade are in development. These include tecarfarin and betrixaban.

Investigational Strategies

New anticoagulants are in development that target various factors of the coagulation cascade.

Additional oral anticoagulant studies for stroke prevention in patients with atrial fibrillation

Drug Target Dose/regimen Study Phase Status Reference
Tecarfarin VKOR 40 mg od (dose adjusted to INR 2.0–3.0) Tecarfarin-CLN-504 II Completed [PubMed]541
Betrixaban Factor Xa 40, 60 or 80 mg od EXPLORE-Xa II Completed [PubMed]542
INR, international normalized ratio; od, once daily; VKOR, vitamin K epoxide reductase.

PDF-File


Where to next?